CoNCERT Pharmaceuticals Inc. Logo (EUIPO, 02/06/2013)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark CoNCERT Pharmaceuticals Inc. was filed as Figurative mark on 02/06/2013 at the European Union Intellectual Property Office.
It was registered as a trademark on 09/04/2015.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Letters presenting a special form of writing
| Trademark form | Figurative mark |
| File reference | 011548931 |
| Application date | February 6, 2013 |
| Publication date | March 21, 2013 |
| Entry date | September 4, 2015 |
| Expiration date | February 6, 2033 |
Trademark owner
99 Hayden Avenue, Suite 500
02421 Lexington
US
02421 Lexington
US
Trademark representatives
Værkmestergade 2
8000 Århus C
DK
Objection / Complaint
goods and services
5
Pharmaceutical preparations; biopharmaceutical preparations; pharmaceutical and biopharmaceutical preparations for veterinary use; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, mood disorders, cognitive disorders, anxiety disorders, alcoholism, central nervous system movement disorders, ocular motility disorders, narcolepsy, pseudo bulbar affect, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, insomnia, bipolar disorder, seizure disorders; pharmaceutical preparations for the treatments of smoking cessation, encephalitis, cerebral palsy, Parkinson's disease, Huntington's disease, fibromyalgia and spinal cord diseases, cancer and cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, diabetic nephropathy, multiple myeloma, HIV, spasticity; pharmaceutical preparations for the relief of pain, pelvic inflammatory disease, inflammatory connective tissue diseases; none of the aforesaid preparations being for the treatment of central nervous system diseases and disorders, namely, attention deficit hyperactivity disorder and/or attention deficit disorder either alone or with related disorders
42
Research and development in the pharmaceutical and biotechnology fields; clinical testing of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 7, 2023 | Extension, Trade mark renewed | ||
| October 3, 2018 | Change Representative, Published |
ID: 11011548931